Systemic Therapy Combinations for Early or Intermediate-Stage HCC: Current Evidence and Ongoing Trials

Download this slideset for expert perspectives on emerging strategies in using immune checkpoint inhibitor combinations for patients with early- and intermediate-stage hepatocellular carcinoma.
Amit G. Singal, MD, MS
Format: Microsoft PowerPoint (.ppt)
File Size: 2.59 MB
Released: November 12, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Related Content

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for gastroesophageal cancers

Manish A. Shah, MD Released: January 21, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers

Rachna Shroff, MD Released: January 21, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for colorectal cancer (CRC)

John L. Marshall, MD Released: January 21, 2022

In this video from Clinical Care Options (CCO), Drs Michael Bishop, Jesús Berdeja, and Jae Park discuss key data on CAR T-cell therapy

Michael R. Bishop, MD
Program Director
person default Jesús G. Berdeja, MD Jae H. Park, MD
Physicians: maximum of 2.25 AMA PRA Category 1 Credits Released: January 13, 2022 Expired: January 12, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings